Patients should seek immediate medical attention for and discontinue semaglutide if they experience: Severe, persistent abdominal pain (possible pancreatitis) Signs of thyroid tumors (neck mass, difficulty swallowing, persistent hoarseness) Symptoms of gallbladder disease (right upper quadrant pain, especially after meals) Severe hypoglycemia (when combined with insulin or sulfonylureas) Signs of kidney problems (decreased urination, swelling, fatigue) Suicidal thoughts or behaviors (particularly with Wegovy) Vision changes (especially in patients with diabetes and pre-existing retinopathy) Regular follow-up with healthcare providers is essential to monitor treatment response, adjust dosing, manage side effects, and assess cardiovascular risk factors including blood pressure, glucose control, and lipid profiles
Because semaglutide can change the absorption rate of warfarin, it may cause your INR levels to fluctuate
Reduced desire to drink in patients treated with semaglutide has raised interest regarding its potential therapeutic benefits for alcohol use disorders
Responsible for labeling: Vetripharm GmbH, Gewerbestrae Sd 7, D-86857 Hurlach Approval number: DE-BY-1-00006 Corresponding declaration concerning minimum storage life and lot reference number can be found on packaging
He also highlighted the complementary biological mechanisms of the two drugs
Grander C, Adolph TE, Wieser V, Lowe P, Wrzosek L, Gyongyosi B, et al
